Peptide Library / Growth Hormone Axis
Tesamorelin
Also known as: —
The most clinically proven GHRH analog — an FDA-approved drug (for HIV-related belly fat) that research circles study for visceral fat specifically.
| Typical research dose | 1–2 mg |
|---|---|
| Frequency | 1× daily (evening, fasted) |
| Route | Subcutaneous injection |
| Cycle length | 12+ weeks (effects build slowly) |
Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.
What it is
Tesamorelin is a stabilized growth-hormone-releasing-hormone analog, and the outlier of this category: it's an actual FDA-approved medication (brand name Egrifta) for reducing visceral abdominal fat in HIV patients with lipodystrophy. That approval means it has real human trial data — for that population and use. Outside that prescription context it remains a research compound.
What the research looks at
- Visceral fat — the signature effect: trials showed ~15–18% reductions in visceral adipose tissue over 6–12 months. Visceral (deep belly) fat is the metabolically dangerous kind.
- IGF-1 elevation — reliable and significant; it's a potent GHRH analog.
- Cognition — smaller studies suggested benefits in older adults.
- Liver fat — studied for NAFLD (fatty liver) reduction.
How protocols are commonly structured
The clinical dose is 2 mg once daily; research-community protocols run 1–2 mg daily, evening, fasted, and expect results on a months, not weeks timeline. It can be layered with Ipamorelin in GH-axis protocols, though it's potent enough that many run it alone.
Reconstitution & storage
Lyophilized powder; bacteriostatic-water reconstitution (calculator). Note the daily dose is in mg — a 10 mg vial is roughly a 5–10 day supply, so this is one of the more consumption-heavy compounds per result.
Research protocols, not a prescription — talk to a physician before touching anything.